Amerikanische Gesellschaft für Hirudotherapie

Platelet aggregation inhibitors from hematophagous animals

Research article published in Toxicon : official journal of the International Society on Toxinology (2010)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Speichel-PharmakologieGenomik & ProteomikFrancischetti I · Toxicon : official journal of the International Society on Toxinology, 2010

Abstract

Salivary glands from blood-sucking animals (e.g., mosquitoes, bugs, sand flies, fleas, ticks, leeches, hookworms, bats) are a rich source of bioactive molecules that counteract hemostasis in a redundant and synergistic manner. This review discusses recent progress in the identification of salivary inhibitors of platelet aggregation, their molecular characterization, and detailed mechanism of action. Diversity of inhibitors is remarkable, with distinct families of proteins characterized as apyrases that enzymatically degrade ADP or as collagen-binding proteins that prevent its interaction with vWF, or platelet integrin α2β1 or GPVI. Molecules that bind ADP, TXA(2), epinephrine, or serotonin with high affinity have also been cloned, expressed, and their structure determined. In addition, a repertoire of antithrombins and an increasingly number of RGD and non-RGD disintegrins targeting platelet αIIbβ3 have been reported. Moreover, metalloproteases with fibrinogen(olytic) activity and PAF phosphorylcholine hydrolase are enzymes that have been recruited to the salivary gland to block platelet aggregation. Platelet inhibitory prostaglandins, lysophosphatydilcholine, adenosine, and nitric oxide (NO)-carrying proteins are other notable examples of molecules from hematophagous salivary secretions (herein named sialogenins) with antihemostatic properties. Sialogenins have been employed as tools in biochemistry and cell biology and also display potential therapeutic applications.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, N.I.H., IntramuralReview
Indexed MeSH termsAnimalsApyraseArthropodsFeeding BehaviorInsect ProteinsModels, BiologicalMolecular Sequence DataPlatelet Aggregation InhibitorsProtein Structure, TertiarySalivary GlandsSequence Alignment

Zusammenfassung

Salivary glands from blood-sucking animals (e. g.

Warum dies für die Hirudotherapie relevant ist

Advances understanding of leech salivary bioactive compounds and their therapeutic potential.

Zitation

Platelet aggregation inhibitors from hematophagous animals.

Francischetti I · Toxicon : official journal of the International Society on Toxinology, 2010

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: March 18, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.